Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Primary Progressive Multiple Sclerosis
NCT01194570Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2011
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Ocrelizumab with Placebo (2 arms). Primary endpoint: Time to Onset of Clinical Disability Progression Sustained for at Least 12 Weeks. Started Mar 2011; status: completed.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT01194570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01194570.